ClinicalTrials.gg
Active, not recruitingNCT06578741Updated Jul 7, 2026

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

An interventional study of GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in Abdominal Aortic Aneurysm, Pararenal Aortic Aneurysm and Thoracoabdominal Aortic Aneurysm, sponsored by W.L.Gore & Associates. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Primary conditionAortic Aneurysm, ThoracoabdominalRegistry: Aortic Aneurysm, AbdominalReclassifiedWhy we changed it
Registry
Aortic Aneurysm, Abdominal — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Aneurysm, Thoracoabdominal
Why
  1. The study's listed conditions name Aortic Aneurysm, Thoracoabdominal, a narrower term within Aortic Aneurysm, Abdominal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by W.L.Gore & Associates · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Aortic Aneurysm, Thoracoabdominal · United States.

Enrollment
4th of 24
310 · median 126
Started
2024
with 1 other
No phase
21 of 26
13 open now
Primary completion
2027-06
later than 5 of 17 live
Registered
25th of 26
by date
Lead sponsor
3 of 26
W.L.Gore & Associates

Among the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 21 with no phase, reaches primary completion later than 5 of the 17 other live ones, and was the 25th registered.

Aortic Aneurysm, Thoracoabdominal

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Open to participants now

15 of the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Aortic Aneurysm, Thoracoabdominal studies recruiting now, 18 (72%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States, or all of them as a file.
02

Study summary

This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.

Read the detailed description

A maximum of 300 adult subjects will be enrolled at up to 60 U.S. centers, with a minimum of 70 subjects enrolled at study centers with no prior experience using the TAMBE Device. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 10 years post implant.

03

Conditions studied

  • Abdominal Aortic Aneurysm
  • Pararenal Aortic Aneurysm
  • Thoracoabdominal Aortic Aneurysm

Browse trials for

04

In context

Aortic Aneurysm, Thoracoabdominal Reclassified

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

This study's enrollment of 310 is above the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Lead sponsor

W.L.Gore & Associates is the lead sponsor of 96 studies on the registry; 20 are open to participants now.

Compared within Aortic Aneurysm, Thoracoabdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Aneurysm, Abdominal. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject is / has:

  1. Treated with the aortic component of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Aortic Component) to allow endovascular repair of an aortic disease involving the visceral vessels.
  2. Age ≥18 years at the time of signature.
  3. An Informed Consent Form signed by subject or legal representative.

Exclusion criteria

Exclusion Criteria:

The subject is / has:

  1. Any for the TAMBE Device according to the IFU.
  2. Planned parallel grafting with the TAMBE Aortic Component.
  3. Intent to modify TAMBE Aortic Component (e.g., in situ fenestration).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
310 participants (actual)

Study arms

  • Other
    Single Arm

    Treatment with GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)

    Device: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)

Interventions

  • DeviceGORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)

    Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms

07

What researchers measure

Primary outcomes

  1. Co-Primary Endpoint #1: Technical Success

    All of the qualifying criteria are met (in the absence of surgical conversion or mortality, type I or type III endoleak, branch occlusion, or graft limb obstruction): * Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits at index procedure. * Successful delivery and deployment of the aortic stent graft and all modular stent graft components at index procedure * Successful side branch catheterization and placement of bridging stents with restoration and maintenance of flow in all intended target vessels at final completion angiography. * Absence of type I or type III endoleaks at final completion angiography. * Patency of all aortic modular stent graft components and intended side branch components at final completion angiography.

    Time frame: Time of index procedure

  2. Co-Primary Endpoint #2: Clinical Success

    All of the following qualifying criteria are met from the initiation of the index procedure through 12 months post-index procedure: * Technical success * Absence of death from the initial procedure, secondary intervention, or aorta-related cause * Absence of persistent type I or type III endoleak * Absence of lesion enlargement \>5 mm * Absence of device migration \>10 mm * Absence of failure due to device integrity issues (defined as Grade 2 or 3 in Table 8) * Absence of lesion rupture * Absence of conversion to open surgical repair * Absence of permanent paraplegia (see definition below) * Absence of disabling stroke (see definition below) * Absence of "loss of function" or "end-stage renal disease" stage according to the RIFLE Classification following the index procedure

    Time frame: Index procedure through 12 months

Secondary outcomes

  1. Target Vessel Technical Success

    Successful catheterization and stent placement in all intended target vessels. Note: For this study, technical success will be reported for the overall procedure and specifically for the vessels targeted for treatment with the branch components (this "target vessel technical success" definition).

    Time frame: 30 days, 6 months, annually through 10 years

  2. Secondary Clinical Success

    Initial clinical success that is interrupted by a treatment failure and is successfully corrected with secondary reintervention (e.g., a patient undergoes a successful treatment of a type I, II, or III endoleak).

    Time frame: 30 days, 6 months, annually through 10 years

  3. Assisted Primary Clinical Success

    Clinical success that is obtained initially and continuously maintained with additional secondary reinterventions thus no interruption to initial clinical success.

    Time frame: 30 days, 6 months, annually through 10 years

  4. Thirty-Day Mortality

    Any death that occurs during the procedure, within the index procedure hospital stay, or within the first 30 days post-index procedure.

    Time frame: 30 days

  5. Lesion-Related Mortality

    Any death that occurs within the first 30 days, or any death that results from lesion rupture, aorta-related complications (e.g., infection, occlusion, dissection, hematoma), or a complication of a secondary intervention.

    Time frame: 30 days, 6 months, annually through 10 years

  6. Major Adverse Events (MAEs)

    Includes any of the following: * All-cause mortality; * Myocardial infarction resulting in severe hemodynamic dysfunction necessitating resuscitation, cardiac arrest, or fatal outcome; * Respiratory failure requiring prolonged (\>24 hours from anticipated) mechanical ventilation or reintubation; * Renal function decline characterized by one or more of the following: * \>50% reduction in baseline Estimated Glomerular Filtration Rate (eGFR); or, * New-onset dialysis; * Bowel ischemia requiring surgical resection or not resolving with medical therapy; * Permanent paraplegia (see "permanent paraplegia" definition below) * Any major stroke

    Time frame: 30 days, 6 months, annually through 10 years

  7. Secondary interventions

    Any Reintervention: Any repeated vascular or nonvascular procedure on the index device (TAMBE Device or any stent or stent graft in contact with any TAMBE component). • Note: Reintervention will be classified as "major", "minor", or "nonvascular" based on the definitions below. Major Reintervention: Deployment of proximal or distal extensions, removal of the device, use of thrombectomy or thrombolysis, and any major open surgical procedure. Minor Reintervention: Endovascular procedures (percutaneous transluminal angioplasty, atherectomy, stenting) without thrombectomy or thrombolysis, interventions to treat branch vessel stenosis, interventions to treat type II endoleaks or branch-related endoleaks, and minor surgical revisions (patch angioplasty) of the access vessels. Nonvascular Reinterventions: Any reinterventions that would not be considered "major reintervention" or "minor reintervention" based on the above definitions.

    Time frame: Time of index procedure

  8. Intraprocedural Complications

    Any vessel perforation, dissection, or occlusion during target vessel cannulation and/or stenting.

    Time frame: 30 days, 6 months, annually through 10 years

  9. Kink

    Objective documentation of demonstrable angulation (localized angle of less than 90 degrees when measured along the centerline) in any of the stent components or native target vessel

    Time frame: 30 days, 6 months, annually through 10 years

  10. Stenosis

    Objective documentation of presence of narrowing with demonstrable flow in any of the components

    Time frame: 30 days, 6 months, annually through 10 years

  11. Occlusion

    Objective documentation of presence of complete stent occlusion with or without minimal flow into a targeted vessel. Note: Occlusions will be stated if they occurred in the aortic component, in a branch component, or in a contralateral leg component used to treat the aortic disease.

    Time frame: 30 days, 6 months, annually through 10 years

  12. Target Vessel Instability

    Any death or rupture related to side branch complication (e.g., endoleak) or any secondary intervention indicated to treat a branch-related complication, including endoleak, disconnection, kink, stenosis, occlusion, or rupture.

    Time frame: 30 days, 6 months, annually through 10 years

  13. Secondary Patency

    Endovascular restoration of patency after occlusion of the side branch, stent, or stent graft has already occurred. Note: Conversion to bypass or inability to treat by endovascular means defines loss of secondary patency.

    Time frame: 30 days, 6 months, annually through 10 years

  14. Primary Assisted Patency

    Endovascular intervention performed to maintain patency in the presence of stenosis before occlusion.

    Time frame: 30 days, 6 months, annually through 10 years

  15. Primary Patency

    Uninterrupted patency with no occlusion or procedure performed to maintain patency on the stent or native target vessel. Note: Interventions intended to treat endoleak or stent disconnection do not count as loss of primary patency.

    Time frame: 30 days, 6 months, annually through 10 years

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Jun 25, 2027
CompletionEst.
Jun 1, 2036
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06578741
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Nov 25, 2024
Primary completion
Jun 25, 2027 (estimated)
Completion
Jun 1, 2036 (estimated)
Last update
Jul 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion